A Study of Safety, Tolerability and Immunogenicity of HPV-L2 Vaccine in Healthy Adult Male and Female Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 28, 2019

Primary Completion Date

May 29, 2020

Study Completion Date

May 29, 2020

Conditions
Papillomavirus Infections
Interventions
BIOLOGICAL

AAVLP-HPV

20μg/injection formulated in a ready to use solution containing 100mM sodium citrate, 2.5 mM MgCl2, 0.001% pluronic F-68, pH 6.0 for i.m. injection as 0.5 mL per injection.

DRUG

Placebo

0.5 mL 100 mM Sodium Citrate, 2.5 mM MgCl2, 0.001% Pluronic F-68, pH 6 for i.m. injection as 0.5 mL per injection.

Trial Locations (1)

BT9 6AD

Celerion Inc., Belfast

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Celerion

INDUSTRY

lead

2A Pharma AB

INDUSTRY